Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Posted on 15 November 2018 | Posted by John Chapman | Posted in Videos, American Heart Association Scientific Sessions 2018

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).

Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

Latest videos

PlayESC 2021 Inclisiran in polyvascular disease
Frederick J. Raal ESC 2021 Inclisiran in polyvascular disease
PlayHuygens: Does PCSK9 inhibition impact the vulnerable plaque?
Steve Nicholls Huygens: Does PCSK9 inhibition impact the vulnerable plaque?
PlayLDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
John Chapman LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
PlayWhy should clinical practice move to an intensive LDL-C lowering approach?
Chris Packard Why should clinical practice move to an intensive LDL-C lowering approach?

« Back to videos